Patents
Literature
5 results about "Immunoglobulin E" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunoglobulin E (IgE) is a type of antibody (or immunoglobulin (Ig) "isotype") that has only been found in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). IgE's main function is immunity to parasites such as helminths like Schistosoma mansoni, Trichinella spiralis, and Fasciola hepatica. IgE is utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum.
Composition comprising an IgE antibody
ActiveUS12606617B2Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsPharmacy medicineIntravenous gammaglobulin
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.
Owner:KINGS COLLEGE LONDON
Heteromultimeric proteins
PCT designated stageWO2026037918A1Hybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsCellular antigensCancer antigen
Described herein are heteromultimeric proteins comprising at least two different polypeptide chains. The polypeptides may comprise Cε3 domain and / or Cε4 domain derived from an immunoglobulin E, and a Cγ2 and / or a Cγ3 domain derived from an immunoglobulin G. The two polypeptide chains may preferentially heterodimerize to promote formation of the heteromultimer. The two polypeptide chains may bind to two different target molecules, e.g. a cancer antigen and a T cell antigen.
Owner:EPSILOGEN LTD
Anti-HER2 antibodies for use in the treatment of low-HER2-expressing tumors in the target population.
In one embodiment, the present invention relates to an anti-HER2 immunoglobulin E (IgE) antibody for use in the treatment of tumors with low HER2 expression in a subject. In another embodiment, the present invention provides an immunoglobulin that binds to HER2.
Owner:EPSILOGEN LTD
Use of lactobacillus casei gkc1 for the preparation of oral compositions for reducing the endotoxin content in serum
The present application relates to the use of Lactobacillus casei GKC1 for preparing an oral composition for reducing the endotoxin content in serum. After the administration of Lactobacillus casei GKC1 to a subject with respiratory allergy, the respiratory resistance of the subject is improved, and the content of immunoglobulin E specific to allergen and the content of endotoxin in the serum of the subject are reduced, so that Lactobacillus casei GKC1 can be used as an effective component of an oral composition for reducing the endotoxin content in serum.
Owner:GRAPE KING BIO LTD
composition
In one aspect, the present invention relates to immunoglobulin E (IgE) antibody for use in treating and / or delaying progression of cancer in a subject, wherein the antibody has a dissociation constant (Kd) for binding to a target antigen of 10 nM or less. In another aspect, immunoglobulins that bind to HER2 are provided.
Owner:EPSILOGEN LTD